Table 3.
Pooled safety results of bevacizumab trials for first-line treatment of advanced breast cancer (E2100, AVADO, RIBBON-1 y
| Severe or life-threatening or fatal adverse events | Pooled chemotherapy (n = 982) | Pooled bevacizumab plus chemotherapy (n = 1679 |
|---|---|---|
| % | % | |
| Any | 23 | 37 |
| Sensory neuropathy | 7.1 | 10 |
| Hypertension | 1.2 | 9 |
| Febrile neutropenia | 3.5 | 6.5 |
| Venous thromboembolic event | 3.8 | 2.8 |
| Proteinuria | 0 | 2.3 |
| Arterial thromboembolic event | 0.3 | 1.6 |
| Left ventricular systolic dysfunction | 1.2 | 1.5 |
| Hemorrhage | 0.4 | 1.5 |
| Abnormal tissue repair | 0.8 | 1.7 |
| Wound dehiscence | 0.3 | 0.8 |
| Fistula | 0.3 | 0.5 |
| Gastrointestinal perforation | 0.5 | |
| Reversible posterior leukoencephalopathy syndrome | 0 | <0.1 |